CELL

What CELL does

CELL Inc. (CELL株式会社) is a Tokyo-based regenerative medicine company founded on June 1, 2018, that provides cell culture contract services, stem cell culture supernatant products, and proprietary acne vaccine R&D to Japanese medical institutions. The company operates two Ministry of Health, Labour and Welfare-approved Cell Processing Centers (CPC) — facility numbers FA3220002 (CELL Bio Lab, Suginami) and FA3250005 (Kioi CELL Bio Lab, Chiyoda) — that perform GMP-compliant manufacturing using Animal Origin Free (AOF) culture medium for stem cells derived from bone marrow, adipose, and umbilical cord sources, as well as immune cells (imDC, activated T cells, CTL, NK cells). The company also markets a clinic-exclusive skincare line (Cellevoque Derma Repair Serum) and NMN infusion preparations to cosmetic and regenerative medicine clinics, pricing products from ¥4,500 (1ml stem cell supernatant) to ¥154,000 (NMN bulk sets).

CELL's core technology platform is built around three differentiated assets: (1) the dual MOHLW-approved CPC infrastructure with cell-specific booths to minimize contamination risk; (2) proprietary antigen peptide technology targeting Propionibacterium acnes, protected by international patents in Japan, Europe, the US, China, and Southeast Asia since 2012; and (3) a three-source stem cell culture supernatant production capability (umbilical cord, bone marrow, adipose), positioning CELL as one of a small number of Japanese manufacturers offering all three source types domestically.

The business operates on a B2B direct-sales model targeting four primary customer segments: medical institutions and regenerative medicine facilities, cosmetic medicine clinics, dermatology and plastic surgery clinics, and research institutions. Revenue is generated through contract cell culture service fees (4-8 week cultivation periods), unit-priced product sales for stem cell supernatant and NMN preparations, and clinic-exclusive product distribution. The company has no disclosed external funding, maintains registered capital of ¥10 million, and is led by President Daisuke Shibuya with a small executive team including two directors and a chief technical advisor.

Name

CELL

Legal name

CELL株式会社

Website

https://cell-inc.org

Company type

Private

Founded year

2018

Operating status

Operating

Short description

CELL Inc. is a Tokyo-based regenerative medicine company founded in 2018 that provides cell culture contract services, stem cell culture supernatant products, and acne vaccine R&D to Japanese medical institutions, operating two MOHLW-approved CPC facilities with international patent coverage.

Ownership category

akta.pro rank

Product category

Regenerative Medicine and Cell Culture Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

NK Cell Therapies (HLAAABAD)

akta.pro secondary industries

Dendritic Cell & Other APC-based Therapies (HLAAABAF), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Cell culture services
• Stem cell manufacturing
• Regenerative medicine
• Acne vaccine research
• Stem cell supernatant

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. 細胞培養受託サービス (Cell Culture Contract Services): Contract cell culture services for medical institutions and research facilities. Covers stem cells (bone marrow, adipose, umbilical cord), immune cells (imDC, activated T cells, CTL, NK cells), and other cell types. Revenue generated through service fees based on cell type, quantity, and cultivation period (approximately 4-8 weeks).
2. 幹細胞培養上清液製品販売 (Stem Cell Culture Supernatant Product Sales): Sale of stem cell culture supernatant products derived from umbilical cord, bone marrow, and adipose tissue. Products available in various volumes (1ml, 5ml) with different pricing. Also includes patch format and exosome preparations.
3. NMN点滴製剤販売 (NMN Infusion Product Sales): Sale of NMN (Nicotinamide Mononucleotide) infusion preparations in various volumes (100ml to 500ml) and bundle sets. Priced from ¥11,000 to ¥154,000 depending on volume.
4. ニキビワクチン製品・化了粧品販売 (Acne Vaccine and Cosmetic Product Sales): Sale of acne vaccine products including injection solutions and patch formats, plus Cellevoque derma repair serum skincare product (30ml, ¥15,800 retail price). Clinic-exclusive products for acne treatment and home care.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

CELL株式会社 provides contracted cell culture services for stem cells and immune cells, develops and sells stem cell culture supernatant (SCCM) products, and conducts R&D on a proprietary peptide-based acne vaccine, all delivered from two Ministry of Health-approved CPC facilities in Tokyo. The company sells its products and services directly to medical institutions, cosmetic medicine clinics, and dermatology/plastic surgery practices in Japan, and also offers NMN infusion preparations and the clinic-exclusive Cellevoque derma repair serum as supporting offerings.

Product overview

CELL株式会社 is a regenerative medicine and aesthetic medicine product development company offering three core services: (1) 細胞培養受託サービス for contracted cell culture of stem cells and immune cells at Ministry-approved CPC facilities; (2) 幹細胞培養上清液研究開発 providing umbilical cord, bone marrow, and adipose-derived stem cell culture supernatant products for medical and cosmetic applications; and (3) 痘痘疫苗研究開発 developing proprietary peptide-based acne vaccines available as injections and microneedle patches, along with the clinic-exclusive skincare product Cellevoque ダーマリペアセラム. The company also provides NMN infusion preparations as part of its product portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• Cellevoque: Clinic-exclusive skincare product line featuring acne vaccine peptides, including Cellevoque Derm Repair Serum (ダーマリペアセラム), marketed for treatment and home care of acne-prone skin

Products and services

• Cell Culture Contract Service (細胞培養受託サービス)
• Stem Cell Culture Supernatant R&D (幹細胞培養上清液研究開発)
• Stem Cell Culture Supernatant Products (幹細胞培養上清液製品)
• NMN Infusion Preparations (NMN点滴製剤)
• Acne Vaccine R&D (ニキビワクチン研究開発)
• Cellevoque Derma Repair Serum (Cellevoque ダーマリペアセラム)

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• 蓮見医院 (Hasumi Clinic)coreStrategic or Co-development PartnerMedical institution partner collaborating on regenerative medicine research and clinical applications. The partnership focuses on accumulating clinical data and demonstrating technology effectiveness in real medical settings.
• ICVS (International Cell Visualization Society)coreStrategic or Co-development PartnerInternational medical research institution partner for clinical data accumulation and technology demonstration in regenerative medicine field.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• ExoCoBio: Korean stem cell-derived exosome company with both therapeutic and aesthetic/cosmetics lines; comparable exosome and stem cell conditioned medium commercial positioning to CELL's supernatant and skincare products.
• CellGenix (Sartorius): Supplier of GMP-grade cell culture media, cytokines, and cell processing services for cell and gene therapy developers; comparable focus on quality-controlled reagents/services feeding stem cell and immune cell culture.

Direct peers

• AnGes: Japanese biotech advancing DNA vaccines and HGF gene therapy in regenerative medicine; comparable Japanese regulatory pathway and biologics development focus to CELL's cell-based and vaccine peptide programs.
• MEDINET: Japanese cell therapy company providing immune cell processing (NK, T-cell) and contract cell manufacturing for clinics and hospitals — most direct overlap with CELL's contract immune cell culture service and CPC-based delivery model.
• Healios: Japanese stem cell therapy company developing MSC-based treatments for indications such as ARDS and stroke; comparable regenerative medicine focus and reliance on cell processing and Japan-centric clinical development.
• Nikon Cell Innovation: Japanese cell processing and regenerative medicine services business offering contract cell manufacturing to medical institutions; directly comparable CPC-based service model and target customer base.

Broad incumbents

• Lonza Cell & Gene Technologies: Global leader in cell therapy contract development and manufacturing (CDMO), including process development and GMP manufacturing; broader scale and geographic scope than CELL but the same underlying business of contract cell processing for clinics and biotechs.
• Maruho: Leading Japanese dermatology specialty pharmaceutical company with treatments for acne, atopic dermatitis, and other skin conditions; directly comparable as the incumbent Japanese player whose market CELL's acne vaccine peptide and Cellevoque brand would compete against.
• JCR Pharmaceuticals: Established Japanese biopharma with a regenerative medicine portfolio (e.g., TEMCELL HS Inj.) and broader biologics franchise; broader but overlapping with CELL's stem cell and immune cell manufacturing scope.

Regional players

• GC Biopharma: Korean biopharma with cell therapy, vaccines, and plasma product franchises; comparable biologics manufacturing and cell-based therapy pipeline though serving primarily a different domestic market.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CELL